Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stafford lies to Peregrine shareholders as seen below with Xencor ownership ties to INmunebio that has a drug INB03 that infringes upon PS Targeting rights and is this why Stafford left Xencor just for legal reasons to go after Peregrine ? Then why why is Xencor stock being accumulated by the same Stafford with Ronin Capital after he leaves Xencor, breaks up PS Targeting rights for Peregrine Shareholders , then sits back as Peregrine shareholders were forced to accept a reduced value deal with Oncologie ...
Why would the Chair Joseph Carleone just sit back and publicly say nothing?? Corruption in the FDA drug approval process is CLEAR to all
_______
INmune Bio Licenses INB03, a First-in Class Innate Immune System Check-Point Inhibitor that Targets Myeloid Derived Suppressor Cells in Cancer
LA JOLLA, CA--(Marketwired - Oct 10, 2017) - INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, announces that it has licensed INB03, a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells, from Xencor, Inc.
Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.
Dr. RJ Tesi, MD, CEO and co-founder of INmune Bio, commented, "INB03 is a novel drug with a unique mechanism-of-action. Xencor has provided us with a complete pre-clinical and manufacturing package that will allow us to enter the clinic quickly."
Dr. Bassil Dahiyat, CEO and founder of Xencor said, "INB03 has novel immune modulating activity and we are excited that the team at INmune Bio are studying its potential in the tumor microenvironment and advancing its development."
The terms of the deal have not been made public. Xencor received an ownership position in INmune Bio and a seat on the Board of Directors.
About INmune Bio: INmune Bio is a private clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing products platforms that reengineer the patient's innate immune system's response to their cancer. The Company's product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
To learn more, please visit www.INmuneBio.com
CONTACT INFORMATION
INmune Bio Contact:
David Moss
CFO
(858) 964-3720
www.INmuneBio.com
Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
https://www.inmunebio.com/index.php/en/news-2/2017/96-inmune-bio-licenses-inb03-a-first-in-class-innate-immune-system-check-point-inhibitor-that-targets-myeloid-derived-suppressor-cells-in-cancer
Stafford lies to Peregrine Pharmaceuticals and the only thing Ronin Capital Management is concerned with is buying up Xencor shares and David Szymkowski in on the puppet show it seems with Roche in tow
Reduction in MDSCs was always part of the MOA of PS Targeting so how many will attempt to profit due to PS Targeting patents?
Why are many MOA of drugs not saying they target flipped PS? Is it because those patents/rights belong to Peregrine Pharmaceuticals where John Springs Stafford came in with one clear mission, to work with hedge fund and move the IP to Oncologie where the current BOD at Avid Bioservices would not stand up for their fiduciary duties?
John Springs Stafford, profiting off all this illegally?
___
From Little Known to IPO: INmune Bio Raises $8.16 Million in Trading Debut
By Jared Whitlock
Monday, February 4, 2019
In the first biotech initial public offering of the year, La Jolla-based INmune Bio took in $8.16 million during its trading debut. The Nasdaq listing also raised the profile of what’s been a quiet operation.
INmune Bio skipped the large funding rounds – and media fanfare – that typically precede an IPO. That was so management could keep control of the company, and because INmune Bio expects its clinical trials will be relatively inexpensive, a company executive said.
The company wants to reengineer the immune system to stop cancer recurrence. During its inaugural day of trading on Feb. 1, INmune Bio sold 1,020,560 shares of common stock at $8 per share.
"Most of the community has not heard of us, and we've done that somewhat on purpose,” Chief Financial Officer David Moss told the San Diego Business Journal.
The company’s INKmune is designed to make NK cells that would otherwise ignore cancer attack the disease. It will start clinical trials in women with refractory ovarian cancer around the end of March, Moss said.
"We focus on properly signaling the NK cells so that they can resume immune surveillance and help clean up residual disease, with the hope that people may not relapse as much,” Moss said.
INmune’s second program, INB03, seeks to inhibit myeloid derived suppressor cells, which often cause treatment resistance. INB03 started a phase 1 trial in Australia in the third quarter of 2018.
INKmune and INB03 could potentially be used alone, together, or in combination with other therapies. They’re aimed at a wide range of cancers.
By holding clinical trials in the United Kingdom and Australia, the company intends to keep costs down. The countries offer tax rebates.
The $8.16 million raised, according to Moss, should advance the programs to Phase 2 trials. From there, he envisions the company turning to grants, partnerships or the public markets -- or all of the above.
"Our belief is that the biotech industry is driven by data. If we drive data for our programs, that will certainly drive value, and that will certainly drive the ability to finance them further,” Moss said.
Although the government shutdown halted IPOs, INmune Bio wasn’t affected. The company got approval to list shares right before the shutdown furloughed U.S. Securities and Exchange Commission employees who review IPO paperwork, but held off on account of the holidays and attention being on the annual J.P. Morgan Healthcare Conference in January.
INmune Bio, which contracts out clinical trial work, has three employees. The company plans to add workers.
Elsewhere in San Diego biotech, Gossamer Bio plans to go public Feb. 8. During the shutdown Gossamer sought to sidestep SEC review, but later reverted to a traditional IPO path with the government reopening.
In addition, Cirius Therapeutics, Cibus and Poseida Therapeutics have put in IPO paperwork, but have yet to list shares.
https://www.sdbj.com/news/2019/feb/04/inmune-bio-raises-816-million-through-ipo/
_____
Corporate Overview
Taking the brakes off of the most powerful weapon in the fight against disease: our immune system
INmune Bio Inc. is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.
INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.
David Szymkowski, PhD
David E. Szymkowski leads the immunology group as Vice President of Cell Biology at Xencor Inc where he is focused on translational development of Fc-engineered and bispecific antibodies for the treatment of autoimmune diseases, allergic diseases, and cancer. Prior to joining Xencor in 2002, Dr. Szymkowski was a principal scientist in the respiratory group at Roche Bioscience in Palo Alto, CA. Previously, he was a virology program leader at Roche Pharmaceuticals in the U.K. With 25 years of big pharma and biotech R&D experience at Roche and at Xencor, Dr. Szymkowski has been instrumental in 10 IND submissions, coauthored over forty papers and reviews, is an inventor on over a dozen patents, and speaks frequently on the development of antibody therapeutics and other biologics. Dr. Szymkowski has contributed to the advancement of numerous antibody drugs into clinical trials for lupus, asthma, allergy, and hematological and solid tumors. He received his B.A. at Johns Hopkins University and his Ph.D. in molecular and cell biology from Penn State, and completed a postdoc at the Imperial Cancer Research Fund (U.K.).
https://quotes.wsj.com/XNCR/company-people
Most Recent Insider Transactions
June 2018 - May 2019
Filing Date Name/Title Shares Transaction Value
05/02/19
Ronin Capital LLC
14,611 Acquisition at $29.87 per share 436,431
03/25/19
Ronin Capital LLC
3,500 Acquisition at $29.77 per share 104,195
03/22/19
Ronin Capital LLC
2,000 Acquisition at $29.96 per share 59,920
03/18/19
Ronin Capital LLC
1,100 Acquisition at $29.90 per share 32,890
03/15/19
Ronin Capital LLC
38,300 Acquisition at $29.02 per share 1,111,466
MDSC; the Most Important Cell You Have Never Heard Of
R.J. Tesi
Published:December 06, 2018
The myeloid-derived suppressor cell (MDSC) is the ‘queen bee’ of the tumor microenvironment. MDSCs protect the cancer from the patient’s immune system, make the tumor resistant to immunotherapy, and allow the tumor to thrive while the patient withers away. Eliminating MDSCs should improve response rates to cancer therapy and patient survival.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(18)30189-5
_________________
John Springs Stafford lied to Peregrine Pharmaceuticals shareholders in some comments and some will stop at nothing to try and have control of the IP because PS Targeting has been proven to be the most upstream FIRST order of event that needs to take place to give any BP IO drug a chance at holding an FDA approval
"such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone."
_________________
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=116251345
Sunday, 08/16/15 04:50:50 PM
Re: 2ndstr2thert post# 230440 0
Post # of 330465
"I do not understand why reducing MDSC'S is a good thing."
I'd read over one of the key Peregrine Pharmaceuticals press releases, where they specifically mention that PS Targeting allows for the reduction by at least ==> because they cleverly said "more than : ) "<== 40% to MDSC's and that is a good thing. Actually, I've said it before in a post or two or more... that "NO OTHER" biotech has ever disclosed that the result of the MOA of any immunotherapy agent was capable of reducing MDSC's by as much as 40%. Now, we must ask more question.... would this large reduction in the area of MDSC's be part of much of the reason why PS Targeting combinations with PD-1/PD-L1..etc..etc allows for a statistically significant percent increase in ORR of 200-300% than without PS Targeting in the mix ? I say yes
I'd read this PR over again and look how Opdivo/Nivolumab/Keytruda..etc..etc makes mention that their drug "INTERACTS" with MDSC's and they never disclose how exactly they interact ?? lol Does Opdivo/Nivolumab/Keytruda..etc..etc and all others reduce MDSC's by 5% or up to at least 40% as Peregrine has revealed. My guess is those other IO drugs do not have anything close to the effect to restore and bring about optimal immune responses as PS Targeting (Bavituximab) does and that is why only Peregrine mentions the 40% reduction number in MDSC's. Next, are they going to be conservative with that percentage ? : ) I say yes...again. Always save the best for when you think you are given the best deal possible by some Big Pharma, then you bring out the best of the best facts that warrants the biggest biotech buyout of all time. Period.... and notice no question marks : ) No exclamation marks neither because one must remain calm at the bargaining table when one knows they have everything all other parties want and to the degree that illegal sabotage attempts/acts would be chosen by some as well.
--------------------------------------------------------
Quote:
February 9, 2015
Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma
PS-Targeting Antibodies Block Tumor Suppression of Immune System Allowing Development of Robust Immune Responses Resulting in Statistically Significant Improvement in Anti-Tumor Activity; Specific Effects Seen in Decreased Levels of MDSCs and Other Immunosuppressive Lymphocytes and Increases in Tumor Fighting Immune Cells
TUSTIN, CA -- (Marketwired) -- 02/09/15 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone. Moreover, cells that suppress the immune system from recognizing tumors, such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone. These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
"These data build on our growing body of encouraging combination data and strengthen our clinical development plans as we evaluate the direction of combination therapy trials utilizing bavituximab and other checkpoint inhibitors" said Jeff T. Hutchins, Ph.D., vice president of preclinical research at Peregrine. "Our goals are to modify a tumor environment that allows more patients to respond to conventional and immune therapy. As the tumor environment switches from immuno-suppressive to immuno-stimulatory with bavituximab treatment, we believe the addition of other checkpoint inhibitors, like anti-PD-1, may increase the number of patients responding to therapy."
In the presentations titled: "Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment", Dr. Freimark and his research group, along with colleagues from the University of Texas Southwestern Medical Center led by Xianming Huang, Ph.D., demonstrate that in immunocompetent preclinical models of breast cancer and melanoma, the combination of PS-targeting antibodies and anti-CTLA-4 and anti-PD1 antibodies demonstrate statistically significant anti-tumor responses than either anti-CTLA-4 or anti-PD-1 antibody alone. New data presented show statistically significant changes in levels of tumor infiltrating lymphocytes (TILs), a type of white blood cell implicated in killing tumor cells, in the PS-targeting and anti-PD-1 combination group over single treatment alone in a melanoma model. Specifically, data show increases in a number of markers used to determine immune activation, including CD3 and CD8 cells expressing PD-1, Lag-3 and CD137 (4-1BB). Furthermore, data show that CD8 T cells in the tumor had increased production of IFN-gamma and TNF-a, both known to assist in promoting immune activation and Granzyme-B which is involved in direct tumor killing.
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=895363
R66, have you considered what Ken Dart has been promised for maintaining his ownership of Peregrine/Avid thru this shifting of some of the IP assets?
Shouldn't Roche (and others) have learned in their high price paid in tranches, to finally buy out Genentech?
The trading pattern (with Stafford types playing ping pong) has, on the surface, held up at 60% ownership. There are some new IIS that boast about long-term plays and...
If there was ever a time for one of them out there to use SEC rules to conceal their holdings, this is the time. There are many a Big Pharma families that know how to play well in the sandbox surrounding drug pricing (recently exposed)
Patent laws were just shaken up in allowing Dana Farber share patents they collaborated on and now, those dozens of collaborations held by Peregrine Pharmaceuticals are quite critical ...as ANY improvement such as Biomarkers etc etc that were developed out of such collaborations is good reason Stafford was the hired gun to confuse what has been going on.
Targeting flipped PS occurs upstream and there are now techniques to prove the order of events that take place ...from Thermo Fisher to GE to Berkeley Lights etc, and some will stop at nothing to hide those facts.
IIS at 85% I would say and there will be some interesting trading days abaj
In another aspect, the surfactant can be an ampholytic surfactant, which possess both positive (cationic) and negative (anionic) charges on the main molecular chains and with their relative counter ions. The cationic part is based on primary, secondary, or tertiary amines or quaternary ammonium cations. The anionic part can be more variable and include sulfonates, as in the sultaines CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate) and cocamidopropyl hydroxysultaine. Betaines such as cocamidopropyl betaine have a carboxylate with the ammonium. Some of the ampholytic surfactants may have a phosphate anion with an amine or ammonium, such as the phospholipids phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, and sphingomyelins.
Examples of surfactants also include, but are not limited to, dodecyl sulfate sodium salt, sodium lauryl sulfate, dodecyl sulfate ammonium salt, secondary alkane sulfonates, alcohol ethoxylate, acetylenic surfactant, and any combination thereof. Examples of suitable commercially available surfactants include TRITON™, Tergitol™, DOWFAX™ family of surfactants manufactured by Dow Chemicals and various surfactants in SURFYNOL™, DYNOL™, Zetasperse™, Nonidet™, and Tomadol™ surfactant families, manufactured by Air Products and Chemicals. Suitable surfactants of surfactants may also include polymers comprising ethylene oxide (EO) and propylene oxide (PO) groups. An example of EO-PO polymer is Tetronic™ 90R4 from BASF Chemicals.
http://www.freepatentsonline.com/y2018/0002571.html
_____
Wonder why Merck is all so quiet on PS Targeting wearable clothing that sensors will be required to target flipped PS
https://www.emdgroup.com/en/news/versum-definitive-agreement-12-04-2019.html
_____
Let's go PS Targeting ... this is far from over and even Udit Batra is well aware how coy Merck and friends can be
CDMO will certainly be busy and when IIS jump into CDMO as it went from 25% to 60% (just what the public sees) then one must ask is there a chance that we are more like 85% shares held in strong hands, even with John Springs Stafford trying to squeeze every last share out of weak hands
Good luck, I doubt anyone of the dozens of medical equipment out there will be able to monitor for levels of Parkinson's Alzheimer's etc etc etc if they don't infringe upon PS Targeting patents
Somebody not happy that the pps has not been lower and I highly doubt some are happy with patent laws
PS Targeting ... Going to be required for many blood tests to track early stage cancers and inflammation will be there
How many shares of CDMO does Brian L Sheehy own?
Very strange that he is an affiliate of The Street and would he have spoken to Jim Cramer lately?
Maybe when collusion is there, it usually spreads like wild fire and interesting times for sure
Would be a perfect time for new BOD Chair etc to do something and request a freezing of all accounts that do not cooperate and then spring on some news
It may be Cohen and Stafford types, only way to communicate some messages, since they don't trust emails or cell phones but one thing is for sure....CDMO is not trading as if any IIS are looking to exit at all
Maybe some unpublished research articles will surface that begin to paint a better picture than what Stafford tried to paint
Flipped PS exists on all stressed and EARLY rogue, diseased cells...and must be targeted early on ( Animals to plants to humans...)
I wonder what value Bayer placed on PS Targeting...maybe enough to join in and play in the Big Pharma sand box
Abstract
The acidity-triggered rational membrane (ATRAM) peptide was designed to target acidic diseases such as cancer. An acidic extracellular medium, such as that found in aggressive tumors, drives the protonation of the glutamic acids in ATRAM, leading to the membrane translocation of its C-terminus and the formation of a transmembrane helix. Compared to healthy cells, cancerous cells often increase exposure of the negatively charged phosphatidylserine (PS) on the outer leaflet of the plasma membrane. Here we use a reconstituted vesicle system to explore how phosphatidylserine influences the interaction of ATRAM with membranes. To explore this, we used two new variants of ATRAM, termed K2-ATRAM and Y-ATRAM, with small modifications at the non-inserting N-terminus. We observed that the effect of PS on the membrane insertion pK and lipid partitioning hinged on the sequence of the non-inserting end. Our data additionally indicate that the effect of PS on the insertion pK does not merely depend on electrostatics, but it is multifactorial. Here we show how small sequence changes can impact the interaction of a peptide with membranes of mixed lipid composition. These data illustrate how model studies using neutral bilayers, which do not mimic the negative charge found in the plasma membrane of cancer cells, may fail to capture important aspects of the interaction of anticancer peptides with tumor cells. This information can guide the design of therapeutic peptides that target the acidic environments of different diseased tissues.
Statement of Significance
Current targeted therapies for cancer have limited success due to drug resistance. Resistance often arises after mutation of the receptor being targeted. A more general target is needed to prevent drug resistance. Most aggressive solid tumors have an extracellular medium. We propose that extracellular acidity is promising for improved targeted therapies. The acidity-triggered rational membrane (ATRAM) inserts in membranes only under acidic conditions. However, it is now known how the lipid changes that occur in the plasma membrane of cancer cells impact the membrane insertion of ATRAM. Here we perform biophysical experiments that show that PS, a lipid exposed in the cancer cell, can impact the membrane insertion of ATRAM. We also uncovered a region of the peptide important for insertion.
https://www.biorxiv.org/content/10.1101/623967v1
________
Who brought in John Springs Stafford and Roger Farley, in order to shift PS Targeting to a 30 day old company Oncologie? The deal made will help all those Big Pharma IO players that require PS Targeting for the most optimal treatment
I wouldn't trust John Springs Stafford at all but like the many others behind him and were like JB paid off, they may have another job for him. Maybe CEO Rahul Desuja (Pelican Therapeutics ex Noble Financial Group ..Peregrine analyst) needs an exec secretary to keep track of the shenanigans
Maybe the Dana Farber lawsuit was a major factor towards "which" path to gear up towards IO combos with PS Targeting
Maybe now, the ruling that collaborations allow some to become co-patent owners and this makes the next set of moves more plausible to set in motion
Maybe now, some will realize that biomarkers "based" on knowledge due to collaborations does not mean one can claim some computer program told them to Target x y z protein pathways etc etc
Maybe now some of the early doubters like Dr Jack West (Bristol Myers Squibb backer), Adam Feuerenstein (BMS backer), Robert S Schwartz (BMS backer) that wrote "Peregrine Pharmaceuticals Bavituximab It's Time To Throw In The Towel on Feb 23, 2013 and there may be some quite convincing evidence why Peregrine was targeted ..
It's a good thing Gordon Freeman did not just throw in the towel and now BMS loses this round and the reason they forked over money to buy Celgene
Gordon Freeman knows exactly how valuable PS Targeting will be and he worked closely with Glen Dranoff that was poached over to Novartis
I wonder who convinced John Springs Stafford to step into this mess, though the fines paid out by hedge funds for collusion will certainly be a risk they had to take it seems
Are you positive?
Try asking Susan MacIntyre whom left Beyond Springs for Oncologie and she sees the benefit of PS Targeting that EVERY IO player will require to adjust that M1/M2 macrophage ratio back to M1
https://www.globenewswire.com/news-release/2019/03/26/1767477/0/en/BeyondSpring-s-Lead-Asset-Plinabulin-Shifts-the-Balance-of-Macrophages-Towards-Anti-Cancer-M1s.html
You may also want to ask the phase 3 Sunrise patients that had Bavituxab before going to Keytruda
Why has not the FDA released that data to the public yet? Some don't want some to find out
Spring time, back to mowing lawns
Did Memorial Sloan Kettering ever clear up the troubles with MDs there utilizing PS Targeting data elsewhere?
Patents for PS Targeting worth Billions and Ronin Capital Management John Springs Stafford the new puppeteer
No wonder why Optera still tries to remain cloaked and maybe Berkeley Lights can shine a light on what has been going on ...
https://www.wbur.org/hereandnow/2019/03/01/immunotherapy-patent-battle
Janssen would be a nice CDMO 1st wave
It will be interesting how they will try to pressure a sale before the 3rd 4th and 5th waves roll in
The buzz is that PS Targeting will be the final momentum wave that disrupts Big Pharma as we now know it and a major lawsuit looms for some that don't realize how to adjust
Maybe John Springs Stafford has time to stop buzzing around and realize how criminal it would be to collude with hedge funds to manipulate CDMO and think again regarding his comments surrounding PS Targeting
Some knew long ago the value of PS Targeting so why did Stafford want a PS Targeting deal finalized before the value was fully realized. Maybe because the value deal made with Oncologie was peanuts
I wonder if some new hedge fund invested in CDMO realizes that the real value driver is PS Targeting and not CDMO. CDMO looks like it will simply be paid off with many manufacturing agreements "based" upon PS Targeting
_________
"Cancer therapies that attack the lipid composition of the cell membrane would be an entirely new class of anticancer drugs," said Paul Beales from the University of Leeds and co-author of the study. "This could be useful in developing new combination therapies, where multiple drugs are used simultaneously to treat a cancer by attacking different parts of the cancer cells at the same time."
In healthy cell membranes, the inner layer (facing the inside of the cell) is packed with phospholipids, including PS (phosphatidylserine) and PE (phosphatidylethanolamine). However, in cancer cells, PS and PE are located on the outer layer of the cell membrane, facing the opposite way.
To test the different effects of PS and PE's presence on a cell, the scientists examined how the MP1 interacted with model membranes infused with PE and/or PS. The presence of each phospholipid had a destructive effect on the cells. PS increased the chance of MP1 binding to the membrane by a factor of seven to eight. The presence of PE inflated the size of the holes created by the MP1 by a factor 20 to 30.
"Formed in only seconds, these large pores are big enough to allow critical molecules such as RNA and proteins to easily escape cells," said João Ruggiero Neto from São Paulo State University and co-author of the study. "The dramatic enhancement of the permeabilization induced by the peptide in the presence of PE and the dimensions of the pores in these membranes was surprising."
The next stage for this research is to adjust the amino acid sequence of MP1 to see what gives it its selective properties, and to try and refine them. "Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," Beales says. "As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."
https://www.iflscience.com/health-and-medicine/brazilian-wasp-venom-kills-cancer-cells-not-healthy-cells/
Collusion with hedge funds trading CDMO stock?
Of course and like Jeanette Bleecker holding a secret book of the real patients and exactly what order of Bavituximab was given and like others following those still living patients that had Bavituximab in Sunrise phase III that went on to another Merckly drug trial....
Have you spoken with Jeff Gramm over at Bandera Partners to ask who was the investor that request to purchase CDMO and who it was that requested to sell?
Things become interesting each step of this long journey where a minor manipulation of hedge sell out here and there still couldn't drop the new IIs from realizing what is going on...
Maybe one should ask Altravue why they purchased or BlackRock why they stayed...heck, maybe BlackRock selling out prior to the sabotage Fargo data where Jeanette Bleecker was paid off ...then buys back in after sabotage was discovered would not look good for BlackRock this time around so they stand still
How many shares did Ken Dart sell? He never filed a sale of shares so looks like that 38% is much higher
It becomes more interesting with groups of collusions going on and I like G-NOs view and let see what happens next
I never knew Teva played well in the sandbox with so many other BPs ...it may not stop at price fixing : )
I also hear Microsoft likes to be Adaptive ..and flipping PS is where it all starts
Would Dave Preston and Heather Preston be sitting around not making a move?
Tracy Saxton brought in and KNEW about PS Targeting (they wanted PS Targeting and how fortunate to have slime Stafford to steer away PS Targeting to Oncologie ) as Heather brought in and now David Preston and some sitting around wondering if they should be greedy ? lol
Advent International and BioDuro and CDMOs and clients and everyone looking for a piece of PS Targeting but now, playing in the sandbox means one is at risk
Let's go Big Pharma, the sandbox is officially broken because all it takes is one to blow the whistle
Tracy Saxton is gone from Pivotal and now more non-disclosure to be sought ...as Pivotal Bioventures have Heather Preston
WestJttr are you positive the value driver is not PS Targeting milestones and royalties and other drugs that possibly infringe upon PS Targeting IP rights ?
Namtro, have you emailed concern to Xencor with their relationships with some BPs like Merck?
One never knows what may happen and when we officially see now proof of BP collusion with drug prices, wouldn't they also collude to steer PS Targeting certain ways?
SOME will like to sell off Avid "before .." anyone has any idea the true magnitude of worth of PS Targeting to Biomarkers to MRIs to blood brain barrier flipping PS entries etc
JDM notice how Lias liked the Myovant phase 3 trial success just within the prior 24 hours
Avid already has a vant CDMO work and why would one vant company CDMO business come Avids way without more
Much more seems to be going on but I wouldn't want an offer in short term from Catalent, wait for FujiFilm that is also well aware of PS Targeting
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118635835
Wonder how Oncologie is doing with their undisclosed clients ( HTG / Mologen / Avid are the only ones they publicly disclosed )
Has Stephen White or John Springs Stafford been introduced to Rahul yet?
They heard the conference call and clearly heard Rahul loud and clear regarding PS Targeting
All are silent ...for now
Laura E Benjamin still working side channels with Eli Lilly or others ...soon
Columbia University must like those PS Targeting research with Akiva Mintz and from Wake Forest School of Medicine to Columbia and he was welcomed because of PS Targeting
Much is being discovered right now and Stafford brought in to shake things up it seems. He certainly lied about the value of PS Targeting and Stafford friends can't even announce a deal on time
Notice how ALL involved with PS Targeting translational knowledge have been given better prestige jobs / patents bought out / made CEOs of companies / the list is endless, even our own Jeanette Bleecker that got caught with the sabotage of phase II at CSM with CEO Gerald Finken all got promotions and $$$$
Heck, we even have an ex Perehrine analyst in Rahul that knew the value of PS Targeting, then promptly made CEO over at Heat Biologics or sub Pelican Therapeutics ...and silenced for now.
Attorney General of CT already hot on the trail of Teva and friends colluding in prices and Merck and friends stomping on PS Targeting are in line for some major headlines
Stafford hired for other reasons to stop the advancement of PS Targeting
https://journals.sagepub.com/doi/full/10.1177/1536012117708722
Acknowledgments
The author would like to pay tribute to the late Dr Philip Thorpe for his pioneered research on phosphatidylserine and development of a series of PS-targeting antibodies. The authors thank Peregrine Pharmaceuticals Inc, Tustin, California, for the provision of PGN635 antibody.
There will not be a $5.50 buyout
Nice try though
Looks like Stafford is concerned these days
Tracy Saxton and Heather Preston would say chump change also
Chump change or 150k shares is all it took to drop the price down after Roger Lias puppet show exiting
Chump change is all it is taking to have GE or was it Thermo Fisher equipment to gauge quality if Biomarkers and certain drugs MOA
Stafford still has no clue but how well do some know David Gaddy at Ronin Capital? Chump investor manipulating Avid CDMO stock?
Granite Investment Partners now with 150+k shares and Stafford friends not happy with the continued build up of shares
It looks to be the pps drop is simply to allow some more cheap shares
What has John Springs Stafford been buying ....more CDMO or one other that would benefit due to CDMO? All puzzle pieces continue for why Stafford needed to break into PPHM BOD
Why is Stafford not returning calls???
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties
10/30/2018
....
...
In addition, Roche is in Phase 1 testing with an undisclosed target. More recently, in 2017, the relationship expanded to include the right to evaluate an additional target with ENHANZE.
https://www.halozyme.com/investors/news-releases/news-release-details/2018/Halozyme-Licenses-New-ENHANZE-Targets-For-25-Million-Upfront-Payment-Future-Milestones-And-Royalties/default.aspx
__________________
Jan 21, 2019
Xencor Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider sale was by John Stafford for US$10.0m worth of shares
https://finance.yahoo.com/news/insiders-selling-xencor-inc-nasdaq-111200201.html
__________________
February 05, 2019
Roche and Xencor double down with cytokine deal
https://www.evaluate.com/vantage/articles/news/snippets/roche-and-xencor-double-down-cytokine-deal
JDM, do you think Xencor and other Halozyme clients have the right to KNOW whom the manufacturing company would be for Halozyme deals?
Do you think Halozyme had some that also leaked their "undisclosed " client and they also had big pharma clients with undisclosed targets
It should be obvious that John Springs Stafford left Xencor for a reason and shows up on the front door to break up Peregrine BOD for some BOD members that would likely vote a certain way
Merck and Alexion and Xencor and the many key players from Frank Torti to Myrtle Potter on both sides will undoubtedly prove that PS Targeting has always been the driving factor in value
CDMO will be given its proper value but remember, CDMO is just to appease some higher level puzzle pieces that are trying, trying not to disrupt the Big Pharma cartel of players
Stafford just another puppet
A concerted effort by some like Graham Dukes or John Braithwaite will expose a grand theft of PS Targeting that almost happened
The many others that accepted $$$ thinking that things were sealed and safe likely have no idea how much bigger this story goes
Katie Couric will also think twice before falling for Merck types again after being used by Merck after news of their fraud
So what happens next?
Hopefully some in the group are threatened as much as some are with cancer. Dukes and Squinto etc must wonder when the game ends
Did Nikoletta truly just happen to end up at Merck friendly IOvanve? lol
This web, with AI Big Data can be solved as easy as PS flipping Biomarkers
Great Point Partners will stay clear away now it seems
Paul Carbone would be a bit disappointed with son Dave Carbone being silenced as well, heck....at least Dave was give President position at IASLC
Did the bylaws change for voting of the BOD with only 6 BOD vs 7 ? Does anyone know if any voting at all can take place with less than 7...
It may be time for another round of letters to the BOD and ask how the communications have been with Oncologie.
How can any voting take place when Oncologie may not be adhering to original terms on transfer of some IP assets
North, interesting with that scenario and pps still strong and rising
Agenus, like Peregrine had a passing of a key MD in their progress for FDA approval
Dr Phil Thorpe and Dr Andrew Parsa ....would the late Dr Parsa have known for how long in how critical it was to Target flipped PS...hmmmm
Maybe CDMO BOD will realize that they may not be able to play dumb for much longer
TOG, did you forget to mention Mark Nathan Lampert? Avid signed a contract with Acumen for ACU-193 re: manufacturing services but that will be newsworthy one day
Who initiated that contract?
The book and movie for this Peregrine Pharmaceuticals saga is becoming one that I bet John Springs Stafford will wish he never got involved in to undermine the shareholders and patent worth of PS Targeting
So we dropped on 100k about shares sold but amazing, big buyers jumping in and price holding strong
May 15 we hear the new IIS as of 3/31/2019 and since April 1 we have seen more IIS building up their shares
MS Jeanette Bleeker couldnt even remember whom at Perceptive she dealt with lol
Roger Lias another puppet down and out
Interim CEO picks up 66k shares and options
So you think the personal matter had to wait till after the new fiscal year started?
Looks like Lias got paid more waiting till after April 30 and I just say ALL things should be questioned
John S Stafford and Roger Farley I am sure like the scenario because Brian Weston algos at Ronin Trading could not loosen up enough shares so now they hope some will fall and sell
Maybe David Gaddy over at Ronin Capital can come up with a better plan of attack?
The PS Targeting IP must be close and either way, the courts will demand an MOA imaging test vs some interesting FDA approvals
I would stick around for the fireworks since deep investigations take some time